Biological evaluation of pyrazinamide liposomes for treatment of Mycobacterium tuberculosis

Int J Pharm. 2007 Feb 7;330(1-2):82-8. doi: 10.1016/j.ijpharm.2006.09.017. Epub 2006 Sep 17.

Abstract

Pyrazinamide liposomes were prepared employing the phospholipid molar ratios; dipalmitoyl phosphatidyl choline (7):cholesterol (2) neutral and dipalmitoyl phosphatidyl choline (7):cholesterol (2):dicetyl phosphate (1) negatively charged. Swelling at 52 degrees C led to higher trapping efficiencies. An optimum sterilizing dose of 25 kGy was exhibited by gamma (gamma)-irradiation. Neutral pyrazinamide liposomes (7:2), swollen for 24 h, were employed in biological evaluation for treatment of mice infected by Mycobacterium tuberculosis. Liposomal pyrazinamide could effect highly significant reduction in bacterial counts (colony forming units/g lung), 10, 20 and 30 days after the last treatment dose. Histopathological examination of mice lungs showed highest severity of infection in drug-free liposomes (control) group > pyrazinamide liposomes > free pyrazinamide 6 days/week. The results indicate high therapeutic efficacy of pyrazinamide liposomes, injected twice weekly, in treatment of M. tuberculosis in mice.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antitubercular Agents / administration & dosage*
  • Antitubercular Agents / chemistry
  • Antitubercular Agents / pharmacokinetics
  • Colony Count, Microbial
  • Injections, Subcutaneous
  • Liposomes / administration & dosage*
  • Liposomes / chemistry
  • Liposomes / pharmacokinetics
  • Lung / microbiology
  • Male
  • Mice
  • Mycobacterium tuberculosis / growth & development*
  • Pyrazinamide / administration & dosage*
  • Pyrazinamide / chemistry
  • Pyrazinamide / pharmacokinetics
  • Random Allocation
  • Tuberculosis / drug therapy*
  • Tuberculosis / metabolism

Substances

  • Antitubercular Agents
  • Liposomes
  • Pyrazinamide